Indaptus therapeutics, inc.INDP.US Overview

US StockHealthcare

(No presentation for INDP)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

INDP Overall Performance

INDP AI Analysis & Strategy

INDP Recent Performance

-1.06%

Indaptus therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

INDP PowerScanner

INDP Key Information

INDP Valuation Metrics

INDP Earnings Table

INDP Profile

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.